☐
|
|
Preliminary Proxy Statement
|
☐
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
|
Definitive Proxy Statement
|
☒
|
|
Definitive Additional Materials
|
☐
|
|
Soliciting Material Pursuant to § 240.14a-12
|
Rigel Pharmaceuticals, Inc.
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
|
☒
|
|
No fee required.
|
|
☐
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
Total fee paid:
|
|
Amount Previously Paid:
|
|
Form, Schedule or Registration Statement No.:
|
|
Filing Party:
|
|
Date Filed:
|